Interestingly, E5 confers resistance to PD-L1 immune checkpoint blockade therapy in patients with head and neck squamous cell carcinoma (HNSCC), via the downregulation of MHC, and Rimantadine has shown therapeutic benefit in patients [10]. This evidence concerns the gene ARHGEF15 and head and neck squamous cell carcinoma.